Simon Suendermann, Joerg Kempfert, Volkmar Falk

The Hybrid Cardiac Surgeon: Way to go or waste of time?

ISSN: 1301-5680
Yayın Aralığı: 4
Başlangıç: 1991
Yayıncı: Bayçınar Tıbbi Yayıncılık

Transcatheter therapies in structural heart diseaseare on a rise, since the first transcatheter aortic valveimplantation (TAVI) in 2006. Numbers of TAVIhave overtaken the number of conventional aorticvalve replacements in certain countries in Europe,for example in Germany, where it was performed forthe first time in 2014.[1] This trend will keep going,particularly as recent prospective, randomized trialsconducted by large-scale pharmaceutical industriesshowed non-inferiority for TAVI even in patientswith a low calculated perioperative risk profile.[2,3]Similar developments can be observed in the fieldof mitral valve disease, albeit with less impact oncardiac surgery. However, the results of the latest

PDF

___

1. Beckmann A, Meyer R, Lewandowski J, Markewitz A, Harringer W. German Heart Surgery Report 2018: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 2019;67:331-344.
2. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
3. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.
4. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 2018;379:2307-18.
5. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297-306.